Voyageur Pharmaceuticals Finalizes Debt Settlement and Adjusts Stock Option Pricing
Calgary, Alberta — April 17, 2026 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSX-V:VM) has finalized its shares for debt settlement and increased the exercise price for stock options granted to company directors and officers.
The Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media announced the completion of the debt settlement, initially disclosed on March 4, 2026. Under the settlement, Voyageur issued 888,888 units at a price of $0.1125 per unit, resolving $100,000 in outstanding debt.
Each unit comprises one common share and one common share purchase warrant. The warrants are exercisable at $0.15 per common share for five years from the issuance date.
Voyageur also announced an increase in the exercise price for 4,300,000 stock options granted to certain directors and officers, also announced on March 4, 2026. The original exercise price of $0.1125 per common share has been increased to $0.15 per common share. Other terms of the options remain unchanged. The repricing is subject to TSX Venture Exchange (TSXV) approval.
Voyageur Pharmaceuticals is focused on developing barium and iodine Active Pharmaceutical Ingredients (API) and aims to offer cost-effective imaging contrast agents. The company is vertically integrating the barium and iodine contrast markets, with plans to produce its own barium, iodine, and new endohedral fullerene drugs (C60). Voyageur has developed five barium contrast products that have Health Canada licenses.
The company intends to generate cash flow through partnerships with established third-party GMP pharmaceutical manufacturers in Canada, ensuring validation of its products by regulatory agencies. Voyageur plans to transition into a high-margin domestic manufacturer of radiology drugs.
Voyageur owns 100% of the Frances Creek barium sulfate (barite) project. The company believes its high-grade mineral resource will replace synthetically produced barium sulfate, resulting in higher quality, lower-cost imaging products.
Voyageur’s goal is to become the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs. The company’s motto is “From the Earth to the Bottle,” highlighting its commitment to responsible sourcing and manufacturing.
Source: Voyageur Pharmaceuticals
Share this story:
